Should leucovorin be fast-tracked as an approved treatment for certain autism symptoms?
Breakthrough or Hype? Leucovorin Gains Attention as Autism Treatment
Leucovorin, a prescription form of folinic acid, is drawing fresh attention for its potential role in treating certain symptoms of autism spectrum disorder (ASD). Long used to counteract the effects of methotrexate chemotherapy and manage folate deficiencies, leucovorin is now being studied for off-label use in children with ASD—particularly those who show signs of cerebral folate deficiency or test positive for folate receptor autoantibodies. Recent media reports have highlighted cases where nonverbal children began speaking after starting leucovorin treatment, fueling debate over whether it should be fast-tracked for FDA approval. While some small-scale studies show promise, experts caution that more robust trials are needed to confirm safety and efficacy. The push for broader access comes amid growing parental demand and political interest. The science is still evolving, but the attention marks a new chapter for this decades-old drug.
Options
- Yes, if backed by solid evidence
- No, more research is needed
- Only for specific cases
- Not sure